Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade D 2.03 0.99% 0.02
AEZS closed up 0.99 percent on Friday, October 20, 2017, on 30 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical AEZS trend table...

Date Alert Name Type % Chg
Oct 20 Crossed Above 50 DMA Bullish 0.00%
Oct 20 200 DMA Resistance Bearish 0.00%
Oct 19 Fell Below 50 DMA Bearish 0.99%
Oct 19 Stochastic Reached Oversold Other 0.99%
Oct 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.98%

Older signals for AEZS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.08
52 Week Low 0.7816
Average Volume 566,852
200-Day Moving Average 2.0984
50-Day Moving Average 2.0168
20-Day Moving Average 2.1085
10-Day Moving Average 2.125
Average True Range 0.1424
ADX 21.31
+DI 22.0
-DI 20.5
Chandelier Exit (Long, 3 ATRs ) 2.0428
Chandelier Exit (Short, 3 ATRs ) 2.3472
Upper Bollinger Band 2.2642
Lower Bollinger Band 1.9528
Percent B (%b) 0.25
BandWidth 14.768793
MACD Line 0.0199
MACD Signal Line 0.0412
MACD Histogram -0.0213
Fundamentals Value
Market Cap 32.7 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -1.19
Price-to-Sales 30.66
Price-to-Book 6.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.20
Resistance 3 (R3) 2.20 2.15 2.17
Resistance 2 (R2) 2.15 2.11 2.15 2.16
Resistance 1 (R1) 2.09 2.08 2.12 2.09 2.15
Pivot Point 2.04 2.04 2.06 2.04 2.04
Support 1 (S1) 1.98 2.00 2.01 1.98 1.91
Support 2 (S2) 1.93 1.97 1.93 1.90
Support 3 (S3) 1.87 1.93 1.89
Support 4 (S4) 1.87